Angela Howes

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 410 citations

Medicine, Immunology, Pharmacotherapy +12

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien et al. · Haematologica · 2017 · 258 citations · Full text

Medicine, Oncology, Pharmacology +15

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Michael Wang, Wojciech Jurczak, Mats Jerkeman et al. · New England Journal of Medicine · 2022 · 216 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer

Stephen R.D. Johnston, Tamas Hickish, Stephen Houston et al. · Journal of Clinical Oncology · 2003 · 196 citations

Medicine, Oncology, Pharmacology +16

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Jean‐Luc Harousseau, Giovanni Martinelli, W Wiktor-Jędrzejczak et al. · Blood · 2009 · 145 citations · Full text

Medicine, Oncology, Pharmacology +11